4//SEC Filing
Cooper Laurence James Neil 4
Accession 0001209191-19-062290
CIK 0001107421other
Filed
Dec 30, 7:00 PM ET
Accepted
Dec 31, 4:37 PM ET
Size
9.4 KB
Accession
0001209191-19-062290
Insider Transaction Report
Form 4
Cooper Laurence James Neil
Chief Executive Officer
Transactions
- Sale
Common Stock
2019-12-30$4.88/sh−110,694$540,187→ 1,733,273 total - Exercise/Conversion
Common Stock
2019-12-27$2.24/sh+44,642$99,998→ 1,843,967 total - Exercise/Conversion
Employee Stock Option (right to buy)
2019-12-27−44,642→ 487,171 totalExercise: $2.24Exp: 2029-01-06→ Common Stock (44,642 underlying)
Footnotes (3)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person to satisfy withholding tax obligations upon the vesting of restricted stock grants.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.79 to $5.14, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]1/12th of the shares underlying this option will vest in equal quarterly installments commencing one quarterly period after 12/31/2018.
Documents
Issuer
ZIOPHARM ONCOLOGY INC
CIK 0001107421
Entity typeother
Related Parties
1- filerCIK 0001641506
Filing Metadata
- Form type
- 4
- Filed
- Dec 30, 7:00 PM ET
- Accepted
- Dec 31, 4:37 PM ET
- Size
- 9.4 KB